Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997264 · ClinicalTrials.gov registry record · Phase 2
Anthrax AV7909 Boost Evaluation Study
A Phase 2 study of Anthrax, sponsored by Biomedical Advanced Research and Development Authority.
- Active
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 7
- Study locations
NCT05997264 is a Phase 2 study of Anthrax that is active but no longer recruiting, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 220 participants, below the 742-participant average among 6 other Anthrax trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05997264, a Phase 2 study of Anthrax, is active but no longer recruiting, sponsored by Biomedical Advanced Research and Development Authority.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 7
- Study locations
Study Summary
This randomized, phase 2, double-blinded, multicenter study is designed to assess the safety and immune response kinetics of CYFENDUS™ (henceforth AV7909) administered on 2 primary series vaccination schedules followed by 6- and 12-month boosters.
Conditions Studied
Interventions
- BIOLOGICAL AV7909 Full Dose (0.5 mL)
- BIOLOGICAL AV7909 Half Dose (0.25 mL)
- BIOLOGICAL Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL)
- BIOLOGICAL Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Study Locations (7)
North Carolina
- Accellacare of Hickory - Hickory
- Accellacare of Salisbury - Salisbury
- Accellacare of Piedmont - Statesville
- Accellacare of Winston-Salem - Winston-Salem
Tennessee
- Accellacare Knoxville - Jefferson City
- Accellacare Knoxville - Knoxville
- Accellacare Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05997264
The ClinicalTrials.gov registry entry for NCT05997264 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 742-participant average among 6 other Anthrax trials with a reported enrollment target (70% lower). The listed sponsor is Biomedical Advanced Research and Development Authority, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anthrax appearing as the primary indexed condition, and to 4 interventions - of which AV7909 Full Dose (0.5 mL) is the first listed.
NCT05997264 reports 7 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05997264 about?
NCT05997264 is a clinical study titled "Anthrax AV7909 Boost Evaluation Study". This randomized, phase 2, double-blinded, multicenter study is designed to assess the safety and immune response kinetics of CYFENDUS™ (henceforth AV7909) administered on 2 primary series vaccination schedules followed by 6- and 12-month boosters.
What is the current status of trial NCT05997264?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2023-12-05. Estimated completion is 2026-08.
What conditions does trial NCT05997264 study?
This clinical trial studies the following conditions: Anthrax.
What interventions are being tested in trial NCT05997264?
The interventions under investigation include: AV7909 Full Dose (0.5 mL) (BIOLOGICAL), AV7909 Half Dose (0.25 mL) (BIOLOGICAL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) (BIOLOGICAL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05997264?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997264 being conducted?
This trial has 7 study locations across North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anthrax
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
COMPLETED · Phase 2
-
Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of AVA-Vaccinated Recipients
RECRUITING
-
VELOCITY: An Anthrax Vaccine Clinical Study
COMPLETED · Phase 3
-
PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine
COMPLETED · Phase 1
-
Anthrax Vaccine Clinical Trials
COMPLETED · Phase 1
-
Febrile Whole Blood Specimen Collection and Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.